<SEC-DOCUMENT>0000950103-18-014809.txt : 20181219
<SEC-HEADER>0000950103-18-014809.hdr.sgml : 20181219
<ACCEPTANCE-DATETIME>20181219083655
ACCESSION NUMBER:		0000950103-18-014809
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181219
FILED AS OF DATE:		20181219
DATE AS OF CHANGE:		20181219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InflaRx N.V.
		CENTRAL INDEX KEY:			0001708688
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38283
		FILM NUMBER:		181242268

	BUSINESS ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745
		BUSINESS PHONE:		49 3641 508180

	MAIL ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Fireman B.V.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp99734_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.65pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.65pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.65pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.65pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.65pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 154pt; text-align: center">SECURITIES AND EXCHANGE
COMMISSION&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.85pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.85pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.10pt; text-align: center">__________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.10pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.45pt; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.45pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">__________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.95pt; text-indent: 15.75pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 190.1pt 0pt 190.7pt; text-align: center; text-indent: -0.7pt">Report
of Foreign Private Issuer</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 190.1pt 0pt 190.7pt; text-align: center; text-indent: -0.7pt">Pursuant to Rule 13a-16 or 15d-16 of</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 190.1pt 0pt 190.7pt; text-align: center; text-indent: -0.7pt">the Securities Exchange Act of 1934</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 190.1pt 0pt 190.7pt; text-align: center; text-indent: -0.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 194.55pt 0pt 194.5pt; text-align: center; text-indent: 0.75pt">December
19, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 194.55pt 0pt 194.5pt; text-align: center; text-indent: 0.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 194.55pt 0pt 194.5pt; text-align: center; text-indent: 0.75pt">Commission
File Number: 001-38283&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.10pt; text-align: center">__________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.10pt; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 209pt 0pt 208.75pt; text-align: center"><B>InflaRx N.V.</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 209pt 0pt 208.75pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.10pt; text-align: center">__________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.10pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 209pt 0pt 208.85pt; text-align: center"><B>Winzerlaer Str. 2</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 209pt 0pt 208.85pt; text-align: center"><B>07745 Jena, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 209pt 0pt 208.85pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 209pt 0pt 208.85pt; text-align: center"><B>(+49) 3641 508180</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.35pt 0pt 154pt; text-align: center">(Address of principal executive
offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.35pt 0pt 154pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.10pt; text-align: center">__________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.10pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">Indicate by check mark whether the registrant files or
will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.4pt 0pt 154pt; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.4pt 0pt 154pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center"></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFLARX
N.V.</FONT></P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 11pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 19, 2018, InflaRx N.V. issued a press release titled &ldquo;InflaRx Receives European Approval to Initiate Phase II Clinical
Trial with IFX-1 in ANCA-Associated Vasculitis.&rdquo;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 11pt 0pt 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-right: 11pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11pt 0pt 6pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center">SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 18.05pt 0pt 6pt; text-indent: 15.15pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Jena, Germany, December 19, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 18.05pt 0pt 6pt; text-indent: 15.15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">INFLARX N.V.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 26%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;/s/ Niels Riedemann</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: &nbsp;</TD>
    <TD>Niels Riedemann</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit</FONT></TD>
    <TD STYLE="width: 89%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Exhibit</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release dated December 19, 2018.</P>

<P STYLE="margin: 0pt 0"></FONT></TD></TR>
</TABLE>




<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp99734_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>EXHIBIT 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>InflaRx Receives European Approval to
Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis </B></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Jena,
Germany, December 19, 2018 &ndash; InflaRx N.V. </B>(Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics
to treat devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, today
announced the approval of an Investigational Medicinal Product Dossier (IMPD) from the European regulatory authorities, allowing
InflaRx to initiate a phase II study with IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with
ANCA-associated vasculitis (AAV).</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">AAV is a
rare and life-threatening autoimmune disease in which activation of the complement system, and specifically generation of C5a,
is believed to play a key role in the neutrophil-driven vessel inflammation that defines the disease. &nbsp;AAV affects approximately
40,000 and 75,000 patients in the United States and Europe, respectively.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Othmar Zenker,
M.D., Chief Medical Officer of InflaRx, said: &ldquo;We are pleased to be able to move forward with the second phase II study
in AAV with IFX-1. AAV is an orphan disease with high unmet medical need. Together with the first study already ongoing in the
US, we have initiated a state-of-the-art phase II program to evaluate the impact of IFX-1 on this often life-threatening disease.&rdquo;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The randomized,
double-blind, placebo-controlled phase II study is planned to enroll approximately 80 patients with AAV at about 60 sites in Europe.
The main objective of the study is to evaluate the efficacy and safety of IFX-1 in this patient population. The study will be
conducted in two parts. Part 1 will compare IFX-1 plus a reduced dose of glucocorticoids versus a standard dose of glucocorticoids,
while part 2 will compare IFX-1 alone versus a standard dose of glucocorticoids. All patients will receive standard of care immunosuppressive
therapy (rituximab or cyclophosphamide). The study is expected to initiate in the first quarter of 2019.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About
IFX-1:</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">IFX-1 is
a first-in-class monoclonal anti-complement factor C5a antibody which highly and effectively blocks the biological activity of
C5a and demonstrates high selectivity towards its target in human blood. Thus, IFX-1 leaves the formation of the membrane attack
complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking
the cleavage of C5. IFX-1 has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically
blocking C5a as a key &ldquo;amplifier&rdquo; of this response in pre-clinical studies. IFX-1 is the first monoclonal anti-C5a
antibody introduced into clinical development and has, to date, successfully completed three clinical phase II studies. To date,
more than 150 people have been treated with IFX-1, which has been shown to be well tolerated. IFX-1 is currently being developed
for various inflammatory diseases, including Hidradenitis Suppurativa and ANCA-associated vasculitis.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><IMG SRC="image_001.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About
InflaRx N.V.:</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">InflaRx (Nasdaq:IFRX)
is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop
first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression
of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries
in Jena and Munich, Germany as well as Ann Arbor, Michigan.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Contacts:</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Investor
Relations</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>InflaRx
N.V.</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Jordan Silverstein</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Head of Corporate
Development and Strategy</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Jordan.silverstein[at]inflarx.de</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">+1-917-837-1709</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Media
Relations</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>MC Services
AG</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Katja Arnold,
Laurie Doyle, Andreas Jungfer</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">inflarx[at]mc-services.eu</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">+49-89-210
2280</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">FORWARD LOOKING
STATEMENTS</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This press
release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements,
which are often indicated by terms such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo;
&ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential&rdquo; or &ldquo;continue&rdquo;
and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements
regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our
ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and
obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our ability to develop
commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition,
liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect
the industry or us and the risks uncertainties and other factors described under the heading &ldquo;Risk Factors&rdquo; in InflaRx&rsquo;s
periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release
and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-</FONT>looking
statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements,
and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future,
except as required by law.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O )<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^L'Q5XJL
M_"FGI<7*-++*VV*%#@N1UY[ ?UK>KAOB+X/O/$L-I<:>5:XMMRF)GVA@V.03
MP""/QJ9MJ/NG=EM/#U,5".)=H=?^'Z'+VGQ(\0>(-?L]/M$M[.*XF5#L3>P4
MGGD^V>PKV&O-_ '@.YT&]?5=6>)9XU*QQ(X;R\CDL?7';W-=_#J%E<R>7!>6
M\KXSM256/Y U-)2M>1V9Y4P;KJG@TE&*W75^O6Q9HK.N->TFTNQ:W&HVT4Y(
M'EM( >>/PJ_O79OW#9C.[/&/6M#Q3F_$/B^/1[L6-M:FZN]H9QOV)&#TW'!^
MN!63HOCN]U+6K:Q>ULF6>0J/(F8L@ ))/'/ ]JYJS*:OKL+WKJ(;NZ>6X9VP
MIC&>">." H]Z]4M$TR8K)9K9N8N%:$*=F1V(Z<4V!RNK^.KFRU>XL[33HIDA
ME6'>TI!9SCL!ZMC\*[>O(-.4ZKXGMBP+?:=1:20'C(4LW;V45Z\2%4LQ  &2
M3VH8D+163-XHT*"4QRZM:*XZCS15NSU2PU!0UG>03@]/+<$_E^!I#.-^(7Q&
M;P3>Z=:0Z>MY)=1R2/OE*!%4J!C@YR3^E<A_POFZ_P"@!#_X$G_XFN;^-.HK
M<_$66)@ MA8Q1[L_WBSG]"OY5Z?X)\ Z W@/1UU/1K2YNI;-'GDFB#,Q<;CD
MGGOB@"EX9^-6DZQJ$5AJ=C-I<\SB.*5G$D+L> "PP5R<8R,<]:].KY'\=Z;8
MZ/XHU[3]+.+6VE(BC4Y\H[ VT'V)./3IVKZJT8SMH>GM=%C<&VC,I;J6VC.?
M?- %ZBJ]]?6NF6$]]>SI!:P(9)97. JCJ:Y;1?B=X9\0ZM#I>ES7D]U*"0OV
M.50JCJS%E  ' SZD>M '8T444 %<+XYU2\M]5LK2UO)[5?(>5S"VW=\P S],
M'\Z[JO)_&<PN/$FI[<86..V!QCYB/\7%- =-I\YTSX7F[<LTC6KR,Q<DEGS@
MY/.>17%:4EW9WJ0:5"#>W$0MXY4^5DR1O<_@.N#CK7<>,S]@\'VU@&!,DD,!
M&>65<$_7[M4? -D9;^]U%@=L2BWB)&03]YB#^0H\P,'5O#\WAYK2&XEAG%VK
MD^6N-K+C.<\D$$<GG/7J*Z72+Z2T^&5U.Y)$*3I%DX^4,54 UF>/+H'Q$@.[
M9:V>6&!U9L\?@M6=55M-^&FFV)=6:X\I& /56.]L<4]Q&%H.@G7;A],,YA2"
MW5VD$8<-S@#!X[9_"NXMM)A\)>$-1B6X,@"2S&3RPOS%<=!]!6;\/823JEV5
MR&D2)&QV49('XM6CX\F\OPK-%Q_I$L</([%AG'X"D!RG@2U+^([;/RFTM&9A
MZEL+_C2^)M?N-<OFL[-G>P#^1' G!N9,XY_V<CCZ$FK'A=_LFG>(M2+M&881
M&C#MA"WYY853\%P!O$NGK)\QC@DD]07PHS]?F//O1YAY%F^\'/HWAJ?49[[9
M/#'YA@AB41 \?+TR>>]+X&M$E\4S3F-08+7.X #+,V.?P!_6MCQ_J %I;:4C
M'S+AQ+* ?^6:GH?4$X%5?!+BQTG7-6E!,*-GW(C3)_4FCH!X/XXN_P"UO&GB
M&<2!XI;QXT8'C8N$X_[Y->BW'QUAM=&^RZ3X>G@EBB$<+W<R>7& ,9.TDG '
M2O.?!&G+XC\9Z+:7"B6*\N3/<QOAMZ8:1P?4$\?C6Y\4?!L7A+Q%%]@5HM,O
M5\RU _Y8R)C* ^W##\?2D4/^'W@G4/&^O1ZMJ*2/I27'VF[N9E(%Y)NSM7^\
M"PR2. ./:MSXM7OBKPWXN62R\1ZE;Z=J,1DMXXY?ECD7 =.1TY5@/<^E>G?#
MGQ2?%G@ZUO)O+6^A)M[M$& )%[@=@PPP'HU>=?&_Q3IU\]KX<MD6>ZM)Q-<3
MKU@;&%C7U9MW(';'<T".:\6_$#4_'&F:/H-K;S[C'$+F(<->76,;1_L \^A)
MR>%KV7X>>!8/!>C_ +W9-JUR ;NX'3V1?11G\3DFO(?@W?:?:?$!$NXHFFNK
M=X;29_\ EE(.6"GH"RY'K\N,\D'Z/H&PHHHH$%>51:3JM[XGWS:9=QPSZAYT
MDOE[5"!L@C/3H.OO7JM% '%^/8+ZZDTU+.QN;E(V>20PID#C _'DUJ>#+"73
M_#D:SQ/%-+(\LD;J05)8\?D!7044 >6>(]-U;4?$>HO'I5VT<SK"LBQ84H %
M)R3]>?I6[XXM+V5=*M[*RNKF. LSF)-V/EVC)]>37;44[@<_X,L)=/\ #L:S
MQ/%-++)*\;@@J2QP#^ %9_CVWO[J'3H[.TGN8UE:2585+=%PN>W4_I7844@.
M4\+Z/+_PA]Q97L#P/=O,62902H8D D?0 UQ4=KK6C7L2K;WD6H0_(CQ1&19!
MTX.,$' ZXKV"BG<#RJ^\.ZU%;V^H7-O=WNHW<A,VT;VBC5<*IQQR2#QZ8J[=
M66JVGP?UN"UTVZ;4KA9E2W5"9#YC;<[?]TY_"O2**0'@7P?\*ZO;>.1J&IZ-
MJ.GPVMG((S<VYC5G8JN ?INXKTSXF^&#XI\%74$ 'VZU/VJT)[R(#\OT92R_
MC78T4 ?*?A'Q=J_AG[?%HL3RW&JPK#%%C)6;^%U7^)\$@#OQZ5WGPH^'5[)J
MK>(_$MG<P/;3%[6"\7$DDQR6F<'T)./?)["D\0?!+5KGQ!?W.AWMC;6<LWVB
MW$KNK0N3N(&U3T?)'/0@5[/IOVT:7:#4O*^W"%?M'E'*&3'S8X'&<T ?.GCG
MP7XBT;QU>7&@:/J-S"9UOK.>SMRRQ.3NVDCN'!_ U]#:)?3ZGH=E>W-I+:7$
8T*M+;RH4:)\?,I!YX.:OT4 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
